ATE203417T1 - Radioaktiv markierte somatostatin - Google Patents

Radioaktiv markierte somatostatin

Info

Publication number
ATE203417T1
ATE203417T1 AT93904844T AT93904844T ATE203417T1 AT E203417 T1 ATE203417 T1 AT E203417T1 AT 93904844 T AT93904844 T AT 93904844T AT 93904844 T AT93904844 T AT 93904844T AT E203417 T1 ATE203417 T1 AT E203417T1
Authority
AT
Austria
Prior art keywords
somatostatin
tumors
administration
hirudin
present
Prior art date
Application number
AT93904844T
Other languages
English (en)
Inventor
Leon Lyle
Raghavan Rajagopalan
Karen Deutsch
Thomas Jeffrey Dunn
Ananthachari Srinivasan
J L Vanderheyden
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/831,724 external-priority patent/US5382654A/en
Priority claimed from US07/831,780 external-priority patent/US5371184A/en
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of ATE203417T1 publication Critical patent/ATE203417T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/68One oxygen atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93904844T 1992-02-05 1993-02-04 Radioaktiv markierte somatostatin ATE203417T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/831,724 US5382654A (en) 1992-02-05 1992-02-05 Radiolabelled peptide compounds
US07/831,780 US5371184A (en) 1992-02-05 1992-02-05 Radiolabelled peptide compounds
US1352793A 1993-02-04 1993-02-04
PCT/US1993/000939 WO1993015770A1 (en) 1992-02-05 1993-02-04 Radiolabelled peptide compounds

Publications (1)

Publication Number Publication Date
ATE203417T1 true ATE203417T1 (de) 2001-08-15

Family

ID=27359884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904844T ATE203417T1 (de) 1992-02-05 1993-02-04 Radioaktiv markierte somatostatin

Country Status (7)

Country Link
EP (2) EP0642357B1 (de)
JP (1) JPH08504166A (de)
AT (1) ATE203417T1 (de)
AU (1) AU3606793A (de)
CA (1) CA2129033A1 (de)
DE (1) DE69330494T2 (de)
WO (1) WO1993015770A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US7238340B1 (en) 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US5480970A (en) * 1993-12-22 1996-01-02 Resolution Pharmaceuticals Metal chelators
US5569745A (en) * 1994-02-25 1996-10-29 Resolution Pharmaceuticals Inc. Peptide-Chelator conjugates
ATE190053T1 (de) * 1994-05-19 2000-03-15 Neorx Corp Aromatische aminsubstituierte liganden mit verbrückten stickstoff-und schwefeldonatoratomen für bildformung
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US6051206A (en) * 1994-06-03 2000-04-18 Diatide, Inc Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
DE19607239A1 (de) * 1996-02-27 1997-08-28 Behringwerke Ag Pharmazeutische Zusammensetzung, enthaltend Hirudin und Verfahren zu deren Herstellung
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
JP2021506886A (ja) * 2017-12-22 2021-02-22 コーネル ユニバーシティー Petおよびチェレンコフ発光画像化に有用な18f標識ペプチドリガンド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4746507A (en) * 1985-04-02 1988-05-24 Salutar, Inc. EDHPA based contrast agents for MR imaging, apparatus and methods
US4746505A (en) * 1985-04-26 1988-05-24 President And Fellows Of Harvard College Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands
US5187264A (en) * 1986-05-28 1993-02-16 Mallinckrodt Medical, Inc. Technetium chelates to be used for determining the renal function
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
AU3098289A (en) * 1988-03-04 1989-09-07 Biogen, Inc. Hirudin peptides
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
GB8914020D0 (en) * 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
CA2026377A1 (en) * 1989-10-03 1991-04-04 John L. Krstenansky Radiolabeled anticoagulant peptides
WO1992005154A1 (en) * 1990-09-14 1992-04-02 Mallinckrodt Medical, Inc. Novel nitrogen-sulfur ligands useful in radiographic imaging agents
JPH06508357A (ja) * 1991-06-03 1994-09-22 マリンクロッド・メディカル・インコーポレイテッド 標識ポリペプチド、その製造法および使用
JPH07503732A (ja) * 1992-02-06 1995-04-20 マリンクロッド・インコーポレイテッド 金属キレート形成速度を高めるためのリガンド類

Also Published As

Publication number Publication date
EP1099693A1 (de) 2001-05-16
EP0642357B1 (de) 2001-07-25
AU3606793A (en) 1993-09-03
WO1993015770A1 (en) 1993-08-19
DE69330494T2 (de) 2002-03-28
EP0642357A4 (en) 1995-04-05
CA2129033A1 (en) 1993-08-19
EP0642357A1 (de) 1995-03-15
JPH08504166A (ja) 1996-05-07
DE69330494D1 (de) 2001-08-30

Similar Documents

Publication Publication Date Title
ATE203417T1 (de) Radioaktiv markierte somatostatin
US5382654A (en) Radiolabelled peptide compounds
DE3682780D1 (de) Mittel fuer die diagnose, die abbildung, die lokalisierung oder die behandlung von tumoren.
Spar et al. 131I‐labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials
EP0217577A3 (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
DE69007881D1 (de) Katheter mit Nadeldichtung.
FI904039A0 (fi) Kelatsbildare foer komplexering av radioaktiva isotoper, dess metallkomplexer och deras anvaendning i diagnostik och terapi.
FI872756A (fi) Med laserstraolning fungerande terapeutisk anordning.
EP0567585A4 (de)
DE69226197T2 (de) Hämoglobine als arzneimittelabgabesystem
DE68903113D1 (de) Tomografisches abbildungssystem fuer stroemungsfelder.
DK202788D0 (da) Nitrogenholdge cykliske ligander, metalkomplekser dannet af disse ligander, diagnostiske praeparater der indeholder disse komplekser samt fremgangsmaade til fremstilling af liganderne
DE3667548D1 (de) Positronenemissionstomographiekamera mit mehrfachschichtendetektoren.
FR2297034A1 (fr) Composition pour la localisation d'isotopes radioactifs en medecine
WO1990003802A3 (en) Technetium imaging agents
NO881560D0 (no) Fremgangsmaate for detektering av begynnende resistens mot terapeutiske midler i kreftpasienter.
DE68906681T2 (de) Röntgenstrahlungsdetektor für Tomographie.
DE68916037D1 (de) Sichtbarmachung von tumoren mit technetiummarkierten kohlenhydraten.
DE3779675D1 (de) 6-(disubstituiertes amino)carbapenam-verbindungen.
BR7607399A (pt) Sistema para exibir visualmente a variacao em radioatividade dentro do ciclo cardiaco de um paciente
DE69117741D1 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
Nogawa et al. Synthesis of 186 Re-DMSA and its biodistributions in mice
BE862329A (fr) Medicament a base de dehydro-oligopeptides destine a la resolution d'une tumeur ou d'un tissu
DE3850962T2 (de) Diagnoseverfahren für leberkrebs.
Hansen The Basis for Preliminary Clinical Trials of Monoclonal Antibodies for Diagnosis and Therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties